Novo Nordisk· @novonordisk · X·· 9 天前精选AI 评分62
AI 导读
诺和诺德发布新闻稿，公布其下一代糖尿病和肥胖在研药物的III期新结果，称这使其独特的amylin创新距离肥胖和糖尿病患者更近一步。完整详情见公司新闻稿链接。
推荐理由
诺和诺德公布下一代糖尿病与肥胖药物III期结果，可了解其amylin创新管线的进展。
正文
#PRESS: New results from phase 3 investigational next-generation diabetes and obesity medicine - taking our unique amylin innovation one step closer to people living with obesity and diabetes.
Get all the details in our press release here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916774
来源：Novo Nordisk · x.com